Regeneracinės medicinos centras, MB - financials and debts
Company age: 2 y. 9 mo.
Regeneracinės medicinos centras - Company finances
|
EUR
|
2024
From: 2024-01-25
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 58,028 | 74,991 |
| Profit before tax | 33,055 | 31,177 |
| Net profit | 33,055 | 29,301 |
| Equity | 33,255 | 41,556 |
| Liabilities | 10,597 | 2,022 |
| Non-current assets | 42,736 | 40,609 |
| Current assets | 1,116 | 2,969 |
| Total assets | 43,852 | 43,578 |
|
Taxes paid
|
||
| STI taxes | - | 11,178 |
|
Financial indicators
|
||
| Revenue change y/y | - | +29.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 75.4% | 67.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.4% | 70.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 57.0% | 39.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 57.0% | 41.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Regeneracinės medicinos centras - Social security debts
The company had no debts to Sodra
Regeneracinės medicinos centras - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-30 | 2025-05-19 | 44.54 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Regeneracines medicinos centras, MB (code 306668002) is a Lithuanian small partnership. In the latest financial year, 2025, the company generated revenue of €75.0K, up 29.2% from €58.0K in 2024. Net profit was €29.3K, slightly below the €33.1K recorded in 2024, while the net profit margin remained solid at 39.1%. The 2024–2025 trend shows stronger sales growth than profit growth, indicating that profitability stayed robust even as costs or the revenue mix changed. The balance sheet remained stable, with total assets of €43.6K in 2025 versus €43.9K a year earlier. Equity increased to €41.6K from €33.3K, while liabilities declined sharply to €2.0K from €10.6K, leaving the company with a very low debt burden. Long-term assets accounted for most of the asset base at €40.6K. Reported ratios for 2025 point to strong efficiency and capital strength: ROE was 70.5%, ROA 67.2%, debt-to-equity 0.05, and asset turnover 1.72x.